The skeletal muscles are the major living component of the human body. They are constituted by stable cells, the myofibres, and by adult multipotent stem cells, the satellite cells, which can multiply to regenerate and repair the damaged tissues. Injections of DNA in muscle cells have been used to produce recombinant proteins with opposite goals: somatic reparation of genetic defects, which needs to elicit no inflammatory or immune response, and DNA vaccination, which needs a robust immune response. Because of possible therapeutical interventions, a growing body of information is being produced dealing with every aspect of the myofibres during inflammatory and autoimmune responses: skeletal muscle-antigen presenting cell (APC) interaction and intrinsic APC capabilities of myoblasts and myocytes, the response to released cytokines and their endogenous production, the regulation of Toll-like receptors and major histocompatibility complex expression. According to these data, the muscle tissue is now emerging no longer as a passive bystander, but more as an active player that, when correctly manipulated, can drive tolerance or immunization to these de novo produced proteins. In the present review, we summarize the recent developments on the control of muscle immune function.
INTRODUCTION
Skeletal muscle tissue represents the major living component of the human body. It is constituted by terminally differentiated, stable cells, the myofibres, a class of large syncytial multinucleated cells, specialized in generating mechanical force. Mature myofibres arise from the fusion of mononucleated satellite stem cells, which can enter a program of proliferation to regenerate and repair the damaged tissue: following a muscle fibre injury, satellite cells transform into activated myoblasts, proliferate and fuse into primitive multinucleated myotubes, which then differentiate into mature muscle fibres. 1, 2 Several factors make skeletal muscle a promising target tissue for gene therapy, to treat local or systemic disorders, as well as for DNA vaccination: tissue abundance, lifetime persistence and easy accessibility to gene delivery systems.
Thanks to the development of skeletal muscle as a novel therapeutic tool, a growing body of information is being produced that analyses every aspect of muscle inflammatory and immune response. Myocytes are emerging as active players in the immune scenario, instead of being passive bystanders: their contribution to the maintenance and amplification of local immune-inflammatory responses is manifest in the expression of a variety of immuno-relevant molecules. The purpose of this review is to summarize the recent literature regarding the multiple aspects of muscle immune function, in view of possible therapeutical interventions.
THE 'YIN/YANG' OF MUSCLE/IMMUNE SYSTEM MODULATION
Inhibition of the immune response is the basis for gene transfer approaches and the target for therapy in idiopathic inflammatory diseases, although DNA vaccination strategies need to elicit a strong immune response.
Muscle tissue has been investigated for gene therapy in order to support a long-term efficient production of recombinant proteins from in situ injected DNA: in particular, naked DNA is receiving considerable attention owing to its safety, simplicity and reliability. 3, 4 Wolff and co-workers presented morphologic evidence that the DNA may enter the mouse skeletal muscle through T-tubules and caveolae: as myocytes have a great number of these structures, this pathway could explain why the muscle tissue internalizes naked DNA better than other tissues. 5 Unfortunately, the transfection efficiency of naked DNA is relatively low, and establishes transgene expression at the injection site alone. Most importantly, the toxicity of the inducer molecule and the immunogenicity of the chimeric transcription factor are the major limitations to the use of this system for human gene and cell therapies: a strong cellular and humoral immune response to the transactivator leads to the loss of transgene expression, probably by the destruction of transgene expressing cells. 6, 7 Gene therapy application would be broadened by developing systems that can finely reduce the potential of eliciting an immune response.
Since their set-up, DNA vaccines have been used to stimulate protective immunity against many infectious pathogens and malignancies, and to induce autoimmune disorders in animal models. 8, 9 Following several veterinary uses of vaccines for species ranging from fish and shrimp to cattle and horses, DNA vaccines for the treatment of cancer have been licensed for use in dogs, fish and horses. 10 A variety of publications describing preclinical and clinical studies of the technologies used to increase the potency of gene-based vaccines, and research further elucidating the immune mechanisms involved, have recently become available. 11 However, the magnitude of immune responses is inversely proportional to animal size, so that the amount of DNA required for effective immunization of primates is much higher (mg versus mg). 12 Many papers have suggested that electroporation improves DNA uptake, antigen production and presentation to the immune system. 13, 14 Such an effect arises from the electricity-induced cell damage, 15 which, thanks to the release of 'danger signals' , increases the inflammatory reaction, initiates the innate immune response, recruits antigenpresenting cells (APCs) along with other immuno-relevant cells, and induces cytokine and chemokine production. 15 DNA vaccines are currently undergoing clinical trials in humans for the prevention of a variety of infections for which the conventional vaccines have failed, including HIV. 8, 9 In spite of many immunostimulatory procedures, DNA vaccine technology still suffers from an inadequate immunogenicity.
TOLL-LIKE RECEPTOR FUNCTION IN MUSCLE CELLS
Skeletal muscle contribution to immune responses has been investigated because of its contribution to the adaptive immune response, while its ability to participate in the innate immune response is less clear. The recent findings that skeletal muscle cells express multiple Toll-like receptors (TLRs) point out the possibility of a response to environmental factors, including pathogens, inflammatory cytokines, hormones and growth factors. 16 TLRs are the main triggers of the innate immune response, not only against infectious pathogens but also to more generic 'danger signals'; 17 they are emerging as an important new family of receptors recognizing unique microbial structures termed pathogen-associated molecular patterns. 18 TLRs are expressed on many cell types, including macrophages and dendritic cells (DCs), on which they initiate microbe recognition. Their engagement triggers proinflammatory cytokine production, enhanced antigen presentation to naive T cells and activation of antigen-specific immune responses; 19 thus, TLRs have a critical role in the induction of acquired as well as innate immunity. The TLR family includes more than 10 members, with different ligand specificities and differential expression among cell types. 20 Interleukin-6 (IL-6) production in response to lipopolysaccharide by human 21 and murine 22 myoblasts suggested that skeletal muscle cells express specific TLRs. 23, 24 As a matter of fact, the expression of TLR2, involved in the response to peptidoglycan and lipoproteins/lipopeptides, 25 TLR4, which recognizes LPS from Gram-negative bacteria, 24 TLR5, which recognizes flagellin from Gram-negative outer membrane, 26 TLR3, which recognizes double-stranded (ds) RNA, suggesting a role in viral recognition, 27 and TLR9, which recognizes unmethylated CpG oligodeoxynucleotides, DNA motifs that are found more commonly in bacterial and viral genomes has been demonstrated ( Figure 1a) . 25 TLR2, TLR4, TLR5 and TLR9 mRNA expression has been found in murine differentiated myotubes as well as in muscles; interestingly, TLR2 and TLR5 were expressed only in murine differentiated myotubes, but not in myoblasts, indicating that the expression of these TLRs is regulated by skeletal muscle cell differentiation. 28 Stimulation of TLR2 and TLR4 elicits robust and equivalent levels of monocyte chemoattractant protein-1 (MCP-1) (CCL2) and KC (CXCL1) mRNA expression in C2C12. 29 The stimulation with Poli(I:C) (an analogue of dsRNA) and interferon-g (IFN-g) upregulates the expression of TLR-3 mRNA in cultured human myoblasts, inducing nuclear factor-kB activation and IL-8 secretion; TLR3 was also detected in biopsies from inflamed and non-inflamed human muscles. 23 TLRs may therefore represent the immune trigger following DNA injection in muscles: vector CpG motifs can act as adjuvants similarly to bacterial CpG, inducing activation of professional APCs, while directly stimulating muscle cell-mediated immune response. 30 Mammalian, bacterial, plasmid and synthetic DNA containing unmethylated CpG dinucleotides in specific sequence contexts are recognized by TLR9 on B cells and on plasmacytoid DCs, triggering IL-12, tumour necrosis factor (TNF)a and IFNa secretion, a critical step in cellular immune response. 31 CpG sequences represent an important cellular mechanism by which DNA vaccines elicit a T-cell response; therefore, the inclusion of stimulatory motifs may be important in the development of DNA-based vaccine for those diseases that require a cell-mediated immunity (for example, HIV, malaria, leishmaniasis and tuberculosis). 32 Early results from ongoing clinical studies indicate that CpG sequences are well tolerated and improve the immune response to microbial vaccines: 29 exogenous CpG motifs added to the fliC gene of Burkholderia pseudomallei enhance flagellin immunogenicity and provide protection against melioidosis. 33 Furthermore, while certain CpG sequences may induce . 29 Selective methylation of the cytosine of the plasmid CpG dinucleotides reduces its ability to stimulate in vitro cytokine production and in vivo antibody or cytotoxic T lymphocyte production. 35 Optimization of vectors for DNA vaccination will probably need the elimination of suppressive motifs and the addition of stimulatory motifs.
Skeletal muscle cells respond to inflammatory molecules
The skeletal muscle has been recently identified as an 'endocrine' organ that, on exertion, produces and releases many cytokines into the circulation, which represent a possible link between physical activity and metabolic changes in the liver, and in adipose tissue. 36, 37 The list of these exercise factors, named 'myokines' , includes IL-6, IL-8 and IL-15. However, the autocrine and in vivo paracrine effects of immunological active molecules, released by myofibres following a local inflammatory injury, are the main interest of this review.
Emerging findings describe muscle cells as a non-immune cell type that, following inflammatory stimuli, may act as a cellular source of mediators, expressing a variety of pro-inflammatory cytokines, chemokines and surface molecules, thus contributing to the maintenance and amplification of local inflammation. The analysis of muscle biopsies by reverse transcription-PCR, immuno-histochemistry and in situ hybridization demonstrated the expression of IL-1a, IL-1b, TNF-a, IL-6, IL-2, IFN-g, MCP-1 and RANTES on inflamed myofibres, besides infiltrating leukocytes and endothelial cells. 38 In vitro, normal human myoblasts respond to inflammatory stimuli by upregulating or inducing the expression of IL-1a, IL-1b, TNF-a, IL-6, IL-8, IL-15, MCP-1 and transforming growth factor-b (TGF-b), whereas IL-4, IL-10 and IFN-g production has never been reported, even under stimulatory conditions. 1,39-41
Muscle cells recruit leukocytes
The expression of cell adhesion molecules (CAMs), cytokine receptors and co-stimulatory molecules in inflamed muscles was demonstrated by in vivo studies on inflammatory myopathy biopsies and by in vitro experiments with myoblast cultures. 1, 38, 42 Intercellular adhesion molecule-1 (ICAM-1) molecules, whose ligand on T cells is LFA-1, are commonly present not only on professional APC, such as macrophages and DCs, but also on target cells involved in inflammatory processes. 43 They are absent in normal muscles, but are observed in all inflammatory myopathies, where they are expressed not only by the endothelium of perimysial arterioles and venules, but also by muscle fibres, especially the non-necrotic ones, which are invaded by mononuclear cells. 38, 44, 45 This distribution suggests that ICAM-1 is involved both in leukocyte-endothelium interactions and in cytotoxicity processes, where it contributes to killing efficiency by creating an intimate contact region in which cytotoxic factors can more easily induce the lethal hit on target cells. 46 ICAM-1 can be shed by the cells and detected as a soluble plasma molecule (sICAM-1). 47 The production of both forms is upregulated in human myoblasts on stimulation with IL-1b, IL-4, IL-6, IFN-g and LPS ( Figure 2a) ; 42, 48 increased levels of sICAM-1 have been detected in the plasma of patients with idiopathic inflammatory myopathies. 49 The binding of sICAM-1 to LFA-1-expressing cells can modulate immune functions through the inhibition of T-cell interactions with APC or target cells. 50 In human myoblasts, the induction of membrane and soluble ICAM-1 expression can be downregulated by TGF-b and IL-10, suggesting that these two cytokines can attain their inhibitory effect, influencing the ongoing inflammatory process in muscle, through modulation of adhesion molecules (Figure 2b) . 51 Chemokine expression in inflammatory myopathies, 38 along with experimental in vitro results showing the effect of different cytokines on chemokine profile in myoblasts, confirms the importance of muscle cells in local leukocyte recruitment: 40 myoblast stimulation with IL-1b, IFN-g and TNF-a induces, with distinct kinetics, expression of the neutrophil-attracting IL-8, as well as of MCP-1, MIP-1a, MIP-3a and RANTES, acting mainly on lymphocytes and monocytes. Among these chemokines, IL-8 has a relatively unique and important role, as it is produced in the early stages of the inflammatory response, but it persists for a prolonged period of time, even for days and weeks; 52 this kinetics distinguishes it from most of the other (Figure 3a) . 53, 54 Muscle cells secrete cytokines IL-6 is a cytokine with a central role in immune-inflammatory reactions; it is secreted by a variety of normal and transformed cells in response to different stimuli, ranging from radiations to chemicals, from infections to autoimmunity. Myoblast IL-6 production is increased by TNF-a, IL-1a, IL-1b, LPS, and IFN-g (Figure 3a) . 21, 42 Human in vitro myoblasts, thanks to membrane-bound glycoprotein130 (gp130), the transducing element of IL-6R, could trigger an autocrine loop in which they respond to self-produced IL-6 through sIL-6R. By using this mechanism, called trans-signalling, they also produce MCP-1 and upregulate membrane bound and soluble ICAM-1 molecules. 55 In vivo trans-signalling dramatically increases the number of potentially IL-6 responsive cells, which are otherwise limited by missing complete IL-6R expression: during acute inflammatory events, infiltrating neutrophils can become a source of sIL-6R through its shedding from the membranes of both living and apoptosing cells. 56 In an in vivo experimental model of myosininduced myositis, IL-6 À/À mice were disease free, with no clinical sign of muscle weakness, or any microscopic evidence of neuromuscular infiltration. 57 In polymyositis biopsies, only those myofibres that were invaded and destroyed by mononuclear cells express high levels of IL-6, MCP-1 and ICAM-1. 44, 58 These findings suggest that IL-6 transsignalling participates in the transition from the acute to the chronic phase of an immune response, and that it can have a much more global role in the regulation of local immune recruitment, while IL-6 acting through the membrane-bound IL-6R regulates the hepatic acute-phase reaction and B-cell stimulation. 59 A control of this form of IL-6-mediated inflammatory response may be used to induce tolerance towards genetically engineered myoblasts, and therefore it can pave the way to successful long-term gene therapy. Jostock et al. 60 demonstrated that the synthetic soluble gp130Fc fusion protein (sgp130Fc) can bind to IL-6/sIL-6R complexes; consequently, a molar excess of sgp130Fc led to a competitive inhibition of the IL-6/IL-6R response, without affecting activities through the membrane-bound IL-6R. sgp130Fc has been successfully used to impair the expression of MCP-1 in a model of air pouch inflammation and to control inflammation in experimental arthritis. 61, 62 The specific blockade of IL-6 trans-signalling may represent an advantage over a global inhibition of the entire IL-6 pathway with neutralizing IL-6R antibodies, which are already being tested in clinical trials (Figure 3b) . 63 Indirect control of myoblast IL-6 trans-signalling can be accomplished by TGF-b, a cytokine with immunosuppressive and anti-inflammatory effects: in an experimental colon-rectal cancer model, an inhibitory effect of TGF-b on IL-6 transsignalling-dependent cell growth has been demonstrated, 64 while in cultured human myoblasts, TGF-b can inhibit IL-1-induced IL-6 secretion (Figure 3b) . 65 Great efforts have been made on the enhancement of the immune response to DNA vaccines through the coadministration of DNA-encoded cytokines, chemokines, co-stimulatory molecules and other experimental adjuvants. Among these, IL-15, a cytokine that stimulates proliferation and activation of T and natural killer cells, has been shown to be a helper immune adjuvant in some animal models of tumours and infectious diseases: it has been tested to induce a Th1 dominant immune response in a model of colon adenocarcinoma and to increase the efficacy of BCG vaccination; 66, 67 thanks to its stimulating effects on natural killer cell proliferation and cytotoxicity, as well as on cytokine production during HIV infection, it has been used to improve the immunogenicity of a gagDNA vaccine in Balb/c mice, resulting in increased antibody-dependent cellular cytotoxicity and complement-dependent lysis of Env-expressing target cells. 68 IL-12 greatly improves antigen-specific cytotoxic T lymphocyte activity and humoral responses in many models. 69, 70 It has been shown that plasmid-encoded IL-12 can augment the immune response after DNA vaccination as it has a key role in Th1 polarization. 71 In this context, we believe that an appropriate stimulation of muscle cell (Figure 2a) , whereas IL-12 is never expressed by muscle cells.
T-LYMPHOCYTES AND MUSCLE INTERACTIONS
Major histocompatibility complex II (MHC II) and classical co-stimulatory molecules (CD80 and CD86) are needed by professional APCs to stimulate naive T cells to proliferate and differentiate. Recent findings regarding the crucial role of DCs, the most potent APCs, in the structure of the immunological synapse and the biological consequences of T cell-DC synaptic patterns are reviewed elsewhere. 72 Here, we will discuss the intrinsic ability of skeletal muscle cells to act as facultative APCs and mediate inflammation.
Intrinsic APC capacities of myoblasts and myocytes
Neither mature muscle fibres in physiological conditions nor cultured human myoblasts under basal conditions express MHC II molecules. The scenario changes in an inflammatory milieu, with a significant upregulation of MHC II antigens: many reports describe the strong expression of human leukocyte antigen-DR (HLA-DR) molecules on the surface of polymyositis muscle fibres, although HLA-DP and -DQ are not detectable. 1,44,73 IFN-g stimulation, alone or in combination with TNF-a, induces the expression of HLA-DR, and later of HLA-DP and -DQ too, on cultured human myoblasts. 42, 74 Thanks to this, human myoblasts are considered non-professional APCs, with the capacity to drive activation and proliferation of CD4 + T cell lines, previously primed for exogenous and endogenous peptides (Figure 4a) . 75, 76 According to the two-signal model of T-cell activation, many reports have been devoted to the investigation of muscle cell repertoire of co-stimulatory molecules: no B7-1 (CD80) or B7-2 (CD86) expression was found either in cultured myoblasts under cytokine stimulation or in inflammatory muscle lesions, 48 while the expression of a yet unidentified B7-related co-stimulatory molecule (BB-1) in muscle fibres of myositis and in muscle cells in vitro has been reported, but its importance in costimulation is still uncertain. 77, 78 Therefore, myoblasts should be considered nonprofessional APCs that maintain a muscle-directed immune response rather than initiating it. New B7 family members have been detected on professional APCs, as well as on other cells in non-lymphoid organs, providing new means for regulating previously activated T cells in peripheral tissues. 79 The first functional new member identified on muscle is the inducible co-stimulator ligand (ICOSL, also known as B7-h, B7-H2), which, according to current models, has a prominent role in the stimulation of effector or memory T cell responses. 80 Its expression in muscles has been demonstrated under in vivo physiological and pathological conditions, as well as in in vitro cultured human myoblasts following TNF-a stimulation. 81 Notably, the presence of a neutralizing anti-ICOSL monoclonal antibody markedly reduced the production of Th1 and Th2 cytokines by activated allogenic CD4 + T cells, when cocultured with myoblasts expressing MHC II and ICOSL. The ICOS-ICOSL interactions can represent an important immunostimulatory pathway for T cell effector functions driving inflammation in muscles. 81, 82 Two other members of this family, the B7-homologue B7-H1 (programmed death ligand-1 PD-L1) and B7-H3, show negative costimulatory effects, pointing out the importance of these molecules in regulating T-cell tolerance and autoimmunity. 79 In specimens of inflammatory myopathies, B7-H1 has been localized on muscle fibres as well as on mononuclear cells, and it can be induced in cultured human myoblasts by IFN-g. 83 In coculture experiments, the presence of a neutralizing anti-B7-H1 antibody markedly enhances the production of IFN-g and IL-2 by pre-activated CD4 + and CD8 + T cells, and the expression of the T-cell activation markers CD25, ICOS, and CD69. 83 Previous conflicting results have been reported about B7-H3 function in APC-T-cell interactions, probably because of differential regulation of more than one B7-H3 receptor. The only report examining the expression and functional relevance of B7-H3 in human muscle supports the hypothesis of an inhibitory role, as a 'rescue' protein for muscle fibres in pathological conditions: it is not detectable on normal muscle fibres, while it is markedly increased on Figure 4 (a) An inflammatory milieu, or genetic manipulations, upregulates HLA-DR and co-stimulatory molecules; among these, the activating ones (ICOSL and CD-40) prevail over inhibitory HLA-G, B7-H1 and B7-H3, while opposite genetic manipulations can upregulate negative co-stimulatory molecules (b).
Skeletal muscle and immune response M Marino et al inflammatory myopathy lesions; 84 in vitro myoblasts and TE671 rhabdomyosarcoma cells have a constitutive and high expression of B7-H3; silencing of B7-H3 in TE671 enhanced CD8 + T-cell-specific lysis, indicating a functional role of B7-H3 in the protection of skeletal muscle from immune-mediated lysis. 84 The discovery of these new members of the B7 family with strong immuno-inhibitory properties in the muscles demonstrates that muscle cells, through modulation of T-cell functions, can finely balance a proinflammatory stimulus: activation of counteracting mechanisms may represent an attempt to protect muscle fibres from the immune attack in inflammatory conditions (Figure 4a ). 85 Modulation of these new B7 family members may therefore become a central strategy to control immune responses after DNA-based gene therapy or vaccination: their correct manipulation can efficiently reduce or enhance local levels of cytokine productions and T-cell activation (Figures 4a and b) .
Another regulatory pathway for T-cell costimulation involves CD40-CD40L interaction. CD40 provides crucial signals for APC activation during humoral and cell-mediated immune responses. CD40 is expressed on a variety of APCs and its ligand, CD40L, is expressed on activated CD4 + and CD8 + T cells; the CD40-CD40L interaction further drives IL-2R expression and antigen-specific T-cell expansion. Several studies described CD40 in non-lymphoid cells too: 86, 87 CD40 ligation results in upregulation of surface molecules and cytokine production in cultured cells. Human myoblasts constitutively express CD40: its levels are synergistically increased by TNF-a and IFN-g, 77 while CD40 ligation increases IL-6, IL-8, IL-15 and MCP-1 production and ICAM-1 expression (Figure 4a) . 38, 58 The CD40-CD40L system found a practical application in gene therapy strategies: the use of a monoclonal antibody against the CD40L inhibited Th cell activation at the time of vector delivery, with a transient prevention of both cellular and humoral immunity. 88 Classical and non-classical MHC I expression The expression of classical MHC I (HLA-ABC) on target cells represents a prerequisite for antigen-specific T-cell-mediated cytotoxicity. The skeletal muscle expresses low levels of MHC I under physiological conditions. 89 In inflammatory muscle diseases, muscle fibres upregulate their MHC I expression; prominent histological features consist of mononuclear cell infiltration (mainly CD8 + T lymphocytes with a restricted TCR repertoire), phagocytosis, necrosis and regeneration of muscle fibres. 90, 91 Human myoblasts constitutively express low levels of classical MHC I antigens, which can be upregulated by IL-1a, IL-1b, TNF-a, IFN-g and MIP-1a, although TGF-b reduces its basal expression (Figures 2a and b) . 42, 51, 92 The expression of classical MHC I molecules allows cell-mediated cytolysis of human myoblasts by activated cytotoxic T lymphocytes. 92 Exogenous antigens can be uptaken, processed and presented by professional APCs into the MHC I pathway to induce CD8+ T-cell responses through a mechanism called cross-priming. There are few sparse professional APCs in the muscle tissue: during DNA vaccination, it is unlikely that they could be directly transfected; myocytes, expressing the transgene, may serve as a reservoir of the antigen, which is then transferred to the APCs recruited by the local inflammatory milieu, and so presented through cross-priming. 93 In addition to classical HLA molecules, muscle fibres express HLA-G in autoimmune inflammatory myopathies and in vitro IFN-gstimulated muscle cells (Figure 4a) . 94 This molecule is structurally related to classical ABC molecules, but differs because of its monomorphism and restricted tissue distribution. HLA-G is considered a tolerogenic antigen with inhibitory effects on immune cells, involved in maternal-fetal tolerance, in graft acceptance, in tissue protection during inflammatory responses and, probably, in tumour dissemination. 95, 96 HLA-G molecules can inhibit cytolysis by cytotoxic T lymphocytes and natural killer cells, and CD4 + T helper functions; its soluble form induces the apoptosis of activated CD8 + T cells. 97 Hence, HLA-G could represent a protective mechanism that is activated following an immune-mediated damage of MHC-expressing target cells and provoked by inflammatory cytokines such as IFN-g. HLA-G expression on human myoblasts, or transfection into TE671 cells, induces a potent inhibition of primary and secondary alloreactive cellular immune responses; 98 together with B7-H1 and B7-H3, it can represent an inhibitory mechanism by which muscle cells might effectively counterbalance an immune-mediated damage (Figure 4b ).
CONCLUDING REMARKS
In the last two decades, research pointed out the active interactions between muscle cells and the immune system. Although myoblasts represent the most widely accepted in vitro system to investigate and characterize the immunobiological properties of the skeletal muscle, at least two other approaches are needed to complete our knowledge of muscle environment: ex vivo biopsies from inflammatory myopathies to explore the histological hallmarks of injury, and in vivo experimental animal models to elucidate the mechanisms underlying the development and maintenance of local immune-inflammatory responses. Any generic inflammatory stimulus, along with activation of muscle TLRs, can trigger cytokine and chemokine production as well as CAM expression, which coordinately can recruit leukocytes for both innate and adaptive immune responses. In this way, myoblasts can become facultative APCs in both MHC I-and MHC II-dependent immune reactions, forming functional immunological synapses with T cells. Expression of HLA-G and of inhibitory B7-family members, as well as inhibitory cytokines similar to TGF-b and IL-10, suggests that this immune response is finely regulated to protect muscle fibres from external pathogens and from excessive inflammatory-immune injuries. Manipulation of this network (either through anti-cytokine/ receptor monoclonal antibodies and sgp130Fc administration or through antisense therapy) can form the basis to block the dysimmune response in pathological conditions similar to inflammatory myopathies, as well as to achieve optimal transgene expression for gene therapy; in DNA vaccination, optimal stimulation of cell-and antibody-mediated reactions can be achieved through interventions on vectors, injection modalities and adjuvants.
